Objectives: We studied the antifungal activity of SCY-078 (an orally bioavailable 1,3-β -d- glucan synthesis inhibitor), micafungin and fluconazole against the planktonic and sessile forms of 178 Candida and non- Candida isolates causing fungaemia in patients recently admitted to a large European hospital. Methods: The in vitro activity of SCY-078, micafungin and fluconazole against the planktonic form of the isolates was assessed using EUCAST EDef 7.3 and CLSI M27-A3. Antibiofilm activity was assessed using the XTT reduction assay. Results: SCY-078 and micafungin showed potent in vitro activity against Candida and non- Candida isolates. The in vitro activity of both drugs was similar, but SYC-078 displayed significantly lower MIC values than micafungin against Candida parapsilosis and non- Candida isolates, whereas micafungin displayed significantly lower MIC values for the remaining species ( P <0.001). In contrast, SCY-078 and micafungin showed essentially the same activity against the biofilms with the exception of Candida glabrata , in which the micafungin sessile MIC values were significantly lower ( P <0.001). These observations were confirmed by assessing biofilm structure by scanning electron microscopy after antifungal treatment. Conclusions: Our study showed that the high in vitro activity of SCY-078 against invasive Candida isolates in both sessile and planktonic forms is comparable to that of micafungin.
Objectives: We studied the antifungal activity of SCY-078 (an orally bioavailable 1,3-β -d- glucan synthesis inhibitor), micafungin and fluconazole against the planktonic and sessile forms of 178 Candida and non- Candida isolates causing fungaemia in patients recently admitted to a large European hospital. Methods: The in vitro activity of SCY-078, micafungin and fluconazole against the planktonic form of the isolates was assessed using EUCAST EDef 7.3 and CLSI M27-A3. Antibiofilm activity was assessed using the XTT reduction assay. Results:SCY-078 and micafungin showed potent in vitro activity against Candida and non- Candida isolates. The in vitro activity of both drugs was similar, but SYC-078 displayed significantly lower MIC values than micafungin against Candida parapsilosis and non- Candida isolates, whereas micafungin displayed significantly lower MIC values for the remaining species ( P <0.001). In contrast, SCY-078 and micafungin showed essentially the same activity against the biofilms with the exception of Candida glabrata , in which the micafungin sessile MIC values were significantly lower ( P <0.001). These observations were confirmed by assessing biofilm structure by scanning electron microscopy after antifungal treatment. Conclusions: Our study showed that the high in vitro activity of SCY-078 against invasive Candida isolates in both sessile and planktonic forms is comparable to that of micafungin.
Authors: Martin Hoenigl; Rosanne Sprute; Amir Arastehfar; John R Perfect; Cornelia Lass-Flörl; Romuald Bellmann; Juergen Prattes; George R Thompson; Nathan P Wiederhold; Mohanad M Al Obaidi; Birgit Willinger; Maiken C Arendrup; Philipp Koehler; Matteo Oliverio; Matthias Egger; Ilan S Schwartz; Oliver A Cornely; Peter G Pappas; Robert Krause Journal: Expert Opin Investig Drugs Date: 2022-06-15 Impact factor: 6.498
Authors: Guillermo Quindós; Katherine Miranda-Cadena; Rosario San-Millán; Katyna Borroto-Esoda; Emilia Cantón; María José Linares-Sicilia; Axel Hamprecht; Isabel Montesinos; Anna Maria Tortorano; Anna Prigitano; Matxalen Vidal-García; Cristina Marcos-Arias; Andrea Guridi; Ferran Sanchez-Reus; Jesús Machuca-Bárcena; Manuel Antonio Rodríguez-Iglesias; Estrella Martín-Mazuelos; Carmen Castro-Méndez; Leyre López-Soria; Alba Ruiz-Gaitán; Marcelo Fernandez-Rivero; Damaris Lorenzo; Javier Capilla; Antonio Rezusta; Javier Pemán; Josep Guarro; Joana Pereira; Célia Pais; Orazio Romeo; Guillermo Ezpeleta; Nerea Jauregizar; David Angulo; Elena Eraso Journal: Front Cell Infect Microbiol Date: 2022-05-16 Impact factor: 6.073
Authors: Mahmoud Ghannoum; Maiken Cavling Arendrup; Vishnu P Chaturvedi; Shawn R Lockhart; Thomas S McCormick; Sudha Chaturvedi; Elizabeth L Berkow; Deven Juneja; Bansidhar Tarai; Nkechi Azie; David Angulo; Thomas J Walsh Journal: Antibiotics (Basel) Date: 2020-08-25
Authors: M Ghannoum; L Long; N Isham; C Hager; R Wilson; K Borroto-Esoda; S Barat; D Angulo Journal: Antimicrob Agents Chemother Date: 2019-09-30 Impact factor: 5.191
Authors: Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks Journal: Drugs Date: 2021-10-09 Impact factor: 9.546
Authors: Ahmed Gamal; Sherman Chu; Thomas S McCormick; Katyna Borroto-Esoda; David Angulo; Mahmoud A Ghannoum Journal: Front Cell Infect Microbiol Date: 2021-03-11 Impact factor: 5.293